Health Condition 1: N461- Oligospermia
Conditions
Interventions
Intervention1: Letrozole Group: Men diagnosed with moderate to severe oligoasthenozoospermia (Including Cryptozoospermia in one of the samples) are treated with letrozole 2.5mg orally, once daily , fo
Sponsors
Jawaharlal Institute of Postgraduate Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subfertile men with moderate to severe oligoasthenozoospermia attending male infertility clinic, WCH, JIPMER during the study period.
Exclusion criteria
Exclusion criteria: 1. Ejaculatory duct obstruction or surgery for male factor infertility 2.History of mumps orchitis, chronic tobacco and alcohol abuse. 3.Ongoing medical treatment including gonadotropins, anabolic steroids, and cancer chemotherapy 4. Leucocytospermia (more than 1 million/ml). 5. Severe varicocele and previously diagnosed Klinefelter syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the effect of letrozole and anastrozole on semen parameters amongst men with Oligoasthenoteratozoospermia.Timepoint: At end of study (2years approx) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To monitor the side effects of letrozole and anastrozole 2. To measure the alterations in serum oestradiol and testosterone produced by letrozole and anastrozole.Timepoint: At end of study (2years approx) | — |
Countries
India
Contacts
Public ContactKubera NS
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed